Effects of preparing techniques and aging on dissolution behavior of the solid dispersions of NF/Soluplus/Kollidon SR: Identification and classification by a combined analysis by FT-IR spectroscopy and computational approaches

Drug Development and Industrial Pharmacy

Volumn 41, Issue 1, 2015, Pages 2-14

  Li, Xiang ^a   Jiang, Chuan ^a   Pan, Lili ^a   Zhang, Haoyang ^a   Hu, Lang ^a   Li, Tianxue ^a   Yang, Xinghao ^a  

^a NANJING NORMAL UNIVERSITY   (China)

Author keywords

Aging; Dissolution; FT IR; Intermolecular interaction; Solid dispersion

Indexed keywords

KOLLIDON PLUS NIFEDIPINE PLUS SOLUPLUS SR; NIFEDIPINE; POVIDONE; UNCLASSIFIED DRUG; MACROGOL DERIVATIVE; POLYVINYL CAPROLACTAM-POLYVINYL ACETATE-POLYETHYLENE GLYCOL GRAFT COPOLYMER; POLYVINYL DERIVATIVE;

AGING; CONTROLLED STUDY; COOLING; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DISSOLUTION; DRUG SYNTHESIS; HYDROGEN BOND; INFRARED SPECTROSCOPY; REVIEW; SCANNING ELECTRON MICROSCOPE; X RAY DIFFRACTION; CHEMISTRY; CLUSTER ANALYSIS; MEDICINAL CHEMISTRY; PROCEDURES; SOLUBILITY;

CHEMISTRY, PHARMACEUTICAL; CLUSTER ANALYSIS; POLYETHYLENE GLYCOLS; POLYVINYLS; POVIDONE; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 84918817900     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2014.938080     Document Type: Review

References (57)

1. Marques IJ, Vaz PD, Fernandes AC, et al. Advantageous delivery of nifedipine from inorganic materials showing increased solubility and biocompatibility. Micropor Mesopor Mat 2014;183:192-200.
2. Yuan XD, Sperger D, Munson EJ. Investigating miscibility and molecular mobility of Nifedipine-PVP amorphous solid dispersions using solid-state NMR spectroscopy. Molecular Pharm 2014;11: 329-37.
3. Ganesh CL, Patil KD, Ghodke D, et al. Preparation and characterization of solid dispersion tablet of furosemide with crospovidone. Res J Pharm Tech 2008;4:386-9.
4. Sinha S, Ali M, Baboota A, et al. Solid dispersion as an approach for bioavailability enhancement of poorly water-soluble drug ritonavir. AAPS PharmSciTech 2010;11:518-27.
5. Han HK, Lee BJ, Lee HK. Enhanced dissolution and bioavailability of biochanin A via the preparation of solid dispersion: in vitro and in vivo evaluation. Int J Pharm 2011;415:89-94.
6. Brabander CD, Mooter GVD, Vervaet C, et al. Characterization of ibuprofen as a nontraditional plasticizer of ethyl cellulose. J Pharm Sci 2002;9:1678-85.
7. Breitenbach J. Melt extrusion: from process to drug delivery technology. Eur J Pharm Biopharm 2002;54:107-17.
8. Breitenbach J, Lewis J. Two concepts, one technology: controlled release and solid dispersion with meltrex. In: Rathbone MJ, Hadgraft J, Roberts MS, Lane ME, eds. Modified-release of drug delivery technology. New York: Marcel Dekker; 2003:125-34.
9. Huang JJ, Wigent RJ, Schwartz JB. Nifedipine molecular dispersion inmicroparticles of ammonio methacrylate copolymer and ethylcel-lulose binary blend for drug controlled delivery. Effect of matrix composition. Drug Dev Ind Pharm 2006;32:1185-97.
10. James EP, James MB, Forster AH, et al. Preparation of glass solutions of three poorly water soluble drugs by spray drying, melt extrusion and ball milling. Int J Pharm 2007;336:22-34.
11. Won DH, Kim MS, Lee S, et al. Improved physicochemical characteristics of felodipine solid dispersion particles by supercritical anti-SE precipitation process. Int J Pharm 2005;301:199-208.
12. Chauhan B, Shimpi S, Paradkar A. Preparation and evaluation of gliben-clamidepolyglycolized glycerides solid dispersions with silicon dioxide by spraydrying technique. Eur J Pharm Sci 2005;26: 219-30.
13. Dong ZD, Chatterji A, Sandhu H, et al. Evaluation of solid state properties of solid dispersions prepared by hot-melt extrusion and solvent co-precipitation. Int J Pharm 2008;355:141-9.
14. Duncan QMC. Review: the mechanism of drug release from solid dispersions in water-soluble polymers. Int J Pharm 2002;231: 131-44.
15. Serajuddin AT. Solid dispersion of poorly water soluble drugs: early promises problems subsequent and recent breakthroughs. J Pharm Sci 1999;88:1058-66.
16. Zajc N, Obreza A, Bele M, et al. Physical properties and dissolution behavior of nifedipine/mannitol solid dispersions prepared by hot melt method. Int J Pharm 2005;291:51-8.
17. Chan KLA, Fleming OS, Kazarian SG, et al. Polymorphism and devitrification of nifedipine under controlled humidity: a combined FT-Raman, IR and Raman microscopic investigation. J Raman Spectrosc 2004;35:353-9.
18. Chutimaworapan S, Ritthidej GC, Yonemochi E, et al. Effect of water-soluble carriers on dissolution characteristics of Nifedipine solid dispersions. Drug Dev Ind Pharm 2000;26:1141-50.
19. Cilurzo F, Minghetti P, Casiraghi A, et al. Characterization of nifedipine solid dispersions. Int J Pharm 2002;242:313-7.
20. Tang XC, Pikal MJ, Taylor LS. A spectroscopic investigation of hydrogen bond patterns in crystalline and amorphous phases in dihydropyridine calcium channel blockers. Pharm Res 2002;19: 477-83.
21. Huang J, Li Y, Wigent RJ, et al. Interplay of formulation and process methodology on the extent of nifedipine molecular dispersion in polymers. Int J Pharm 2011;420:59-67.
22. Aaltonen J1, Gordon KC, Strachan CJ, et al. Perspectives in the use of spectroscopy to characterise pharmaceutical solids. Int J Pharm 2008;364:159-69.
23. Rumondor ACF, Taylor LS. Effect of polymer hygroscopicity on the phase behavior of amorphous solid dispersions in the presence of moisture. Mol Pharm 2010;7:477-90.
24. Rumondor ACF, Marsac PJ, Stanford LA, et al. Phase behavior of poly(vinylpyrrolidone) containing amorphous solid dispersions in the presence of moisture. Mol Pharm 2009;6:1492-505.
25. Mukharya A, Chaudhary S, Mansuri N, et al. Solid-state characterization of lacidipine/PVP K(29/32) solid dispersion primed by SE co-evaporation. Int J Pharm Invest 2012;2:90-6.
26. Gorajana A, Rajendran A, Dua K, et al. Preparation, characterization, and in vitro evaluation of nitrendipine solid dispersions. J Disper Sci Technol 2012;33:676-84.
27. Hirasawa N, Ishise S, Miyata H, et al. Physicochemical characterization and drug release studies of nilvadipine solid dispersions using water-insoluble polymer as a carrier. Drug Dev Ind Pharm 2003;29:339-44.
28. Bandarkar FS, Vavia PR. An optimized commercially feasible milling technique for molecular encapsulation of meloxicam in beta-cyclodextrin. Drug Dev Ind Pharm 2011;37:1318-28.
29. Aggarwal AK, Singh S. Physicochemical characterization and dissolution study of solid dispersions of diacerein with polyethylene glycol 6000. Drug Dev Ind Pharm 2011;37:1181-91.
30. Fu JJ, Xu LS, Wang XL, et al. Nimodipine (NM) tablets with high dissolution containing NM solid dispersions prepared by hot-melt extrusion. Drug Dev Ind Pharm 2001;37:934-44.
31. He HB, Yang R, Tang X, et al. In vitro and in vivo evaluation of fenofibrate solid dispersion prepared by hot-melt extrusion. Drug Dev Ind Pharm 2010;36:681-7.
32. Garg A, Singh S, Rao VU, et al. Solid state interaction o raloxifene HCl with different hydrophilic carriers during co-grinding and its effect on dissolution rate. Drug Dev Ind Pharm 2009;35:455-70.
33. Liu H, Zhou LL, Wei LL, et al. Preparation of budesonide-poly (ethylene oxide) solid dispersions using supercritical fluid technology. Drug Dev Ind Pharm 2007;33:959-66.
34. Chen SJ, Zhu JB, Ma FQ, et al. Preparation and characterization of solid dispersions of dipyridarmole with a carrier "copolywidonum Plasdone (R) S-630". Drug Dev Ind Pharm 2007;33:888-99.
35. Ren FZ, Jing QF, Tang YH, et al. Characteristics of bicalutamide solid dispersions and improvement of the dissolution. Drug Dev Ind Pharm 2006;32:967-72.
36. Li L, AbuBaker O, Shao ZZJ. Characterization of poly(ethylene-oxide) as a drug carrier in hot-melt extrusion. Drug Dev Ind Pharm 2006;32:991-1002.
37. El-Badry M, Fathy M. Enhancement of the dissolution and permeation rates of meloxicam by formation of its freeze-dried solid dispersions in polyvinylpyrrolidone K-30. Drug Dev Ind Pharm 2006;32:141-50.
38. Aaltonen J1, Gordon KC, Strachan CJ, et al. Perspectives in the use of spectroscopy to characterise pharmaceutical solids. Drug Dev Ind Pharm 2008;364:159-69.
39. Mohammadreza K, Bagheri GA, Mehdi R, et al. Diagnosis of renal failure by infrared spectrometric analysis of human serum samples and soft independent modeling of class analogy. Microchemical J 2013;106:67-72.
40. Massart DL, Kaufman L. The interpretation of analytical chemical data by the use of cluster analysis. New York: Wiley; 1983: vol. 273: 75-101.
41. Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 1997;86: 1-12.
42. Smikalla MM, Urbanetz NA. The influence of povidone K17 on the storage stability of solid dispersions of nimodipine and polyethylene glycol. Eur J Pharm Biopharm 2007;66:106-20.
43. Taylor LS, Zografi G. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm Res 1997;14:1691-8.
44. Miyazaki T, Yoshioka S, Aso Y, et al. Ability of polyvinylpyrroli-done and polyacrylic acid to inhibit the crystallization of amorphous acetaminophen. J Pharm Sci 2004;93:2710-7.
45. Gupta P, Thillagavathi R, Chakraborti AK, et al. Role of molecular interaction in stability of celecoxib-PVP amorphous systems. Mol Pharm 2005;2:384-91.
46. Matsumoto T, Zografi G. Physical properties of solid molecular dispersions of indomethacin with poly(vinylpyrrolidone) and poly (vinylpyrrolidone-co-vinylacet-ate) in relation to indomethacin crys tallization. Pharm Res 1999;16:1722-8.
47. Taylor LS, Zografi G. Sugar-polymer hydrogen bond interactions in lyophilized amorphous mixtures. J Pharm Sci 1998;87:1615-21.
48. Karavas E, Georgarakis E, Sigalas MP, et al. Investigation of the release mechanism of a sparingly water-soluble drug from solid dispersions in hydrophilic carriers based on physical state of drug, particle size distribution and drug-polymer interactions. Eur J Pharm Biopharm 2007;66:334-7.
49. Konno H, Taylor LS. Ability of different polymers to inhibit the crystallization of amorphous felodipine in the presence of moisture. Pharm Res 2008;25:969-78.
50. Marsac PJ, Konno H, Taylor LS. A comparison of the physical stability of amorphous felodipine and nifedipine systems. Pharm Res 2006;23:2306-16.
51. Tang XLC, Pikal MJ, Taylor LS. The effect of temperature on hydrogen bonding in crystalline and amorphous phases in dihydropyrine calcium channel blockers. Pharm Res 2002;19: 484-90.
52. Rumondor ACF, Ivanisevic I, Bates S, et al. Evaluation of drug-polymer miscibility in amorphous solid dispersion systems. Pharm Res 2009;26:2523-34.
53. Kestur US, Taylor LS. Role of polymer chemistry in influencing crystal growth rates from amorphous felodipine. Cryst Eng Commun 2010;12:2390-97.
54. Chen C, Xie XB, Li Y, et al. Influence of different polymers on crystallization tendency and dissolution behavior of cilnidipine in solid dispersions. Drug Dev Ind Pharm 2013;40: 441-51.
55. Datta S, Grant DJW. Crystal structures of drugs: advances in determination, prediction and engineering. Nat Rev Drug Discov 2004;3:42-57.
56. 2) for dissolution profile comparisons of extended release formulations: how and when do they match? Pharm Res 2011;28:1144-56.
57. Moore JW, Planner HH. Mathematical comparison of dissolution profiles. Pharm Technol 1996;20:64-74.